iTeos Therapeutics, Inc. (ITOS)

Compare

7.34

+0.01

(+0.20%)

As of 2:05:44 PM EST. Market Open.

iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo

Wells Fargo lowered the firm’s price target on iTeos Therapeutics (ITOS) to $19 from $31 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended b

TipRanks 10 days ago

ITOS
+0.20%
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy

iTeos' Phase II trial for inupadenant met its primary and secondary endpoints but offered little more than existing treatments.

Clinical Trials Arena 17 days ago

ITOS
+0.20%
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts- Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS- Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed- Inupadenant deprioritized to

GlobeNewswire 18 days ago

ITOS
+0.20%
iTeos to Participate in Upcoming Investor Conferences

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December: 7Th Annual Evercore HealthCONx ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: Tuesday, December 3, 2024Time: 9:35

GlobeNewswire last month

ITOS
+0.20%
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Last week, you might have seen that iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) released its third-quarter result to the...

Simply Wall St. last month

ITOS
+0.20%
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO- Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination- Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful

GlobeNewswire last month

ITOS
+0.20%
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that preclinical, translational, and clinical data from inupadenant will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2024, being held December 11-13, 2024 in G

GlobeNewswire 2 months ago

ITOS
+0.20%
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.

Investor's Business Daily 3 months ago

NUVL

ITOS
+0.20%
ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm.

Pharmaceutical Technology 3 months ago

ITOS
+0.20%
TIGIT drug from iTeos shrinks lung tumors in trial

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

BioPharma Dive 3 months ago

ITOS
+0.20%
MRK

ROG.SW
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy- Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations- GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting- iTeos to host a conferenc

GlobeNewswire 3 months ago

ITOS
+0.20%
We're Keeping An Eye On iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 4 months ago

ITOS
+0.20%
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that interim data from GALAXIES Lung-201, the Phase 2 platform study sponsored by iTeos’ development partner GSK, assessing the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally

GlobeNewswire 4 months ago

ITOS
+0.20%
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates

iTeos Therapeutics (ITOS) delivered earnings and revenue surprises of 82.69% and 733.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

ITOS
+0.20%
XOMA
iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates

- Multiple clinical milestones across portfolio anticipated in second half of 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Pro forma cash and investment balance of $714.4 million as of June 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company

GlobeNewswire 4 months ago

ITOS
+0.20%
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company’s clinical development and regulatory strategies. “As iTeo

GlobeNewswire 4 months ago

ITOS
+0.20%
iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial

iTeos will receive $35m from GSK as the first patient is dosed in the Phase III trial of the jointly developed monoclonal antibody EOS-448.

Pharmaceutical Technology 5 months ago

ITOS
+0.20%
GSK

GLDAF
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the dosing of the first patient in GALAXIES Lung-301, a global, randomized, double-blind Phase 3 registrational clinical trial of belrestotug + dostarlimab versus placebo + pembrolizumab in patients with firs

GlobeNewswire 5 months ago

ITOS
+0.20%
iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC

Progression-free survival and overall survival are the trial’s primary endpoints.

Clinical Trials Arena 6 months ago

ITOS
+0.20%
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, and its development partner GSK, have initiated the first, global Phase 3 registration study of belrestotug + dostarlimab doublet versus placebo + pembrolizumab in patients with previously untreated, unresectable, locally ad

GlobeNewswire 6 months ago

ITOS
+0.20%

Performance Overview

Return	ITOS	S&P 500
YTD	-33.01%	+24.39%
1-Year	-33.01%	+24.39%
3-Year	-84.09%	+23.79%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

iTeos Therapeutics, Inc. (ITOS)

iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo

Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

iTeos to Participate in Upcoming Investor Conferences

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

TIGIT drug from iTeos shrinks lung tumors in trial

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

We're Keeping An Eye On iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn Rate

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates

iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates

iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

Performance Overview